Disc Medicine, Inc. IRON 深 沪
等待开盘 04-01 09:30:00 美东时间
63.94
+3.160
+5.20%
华盛通- 最 高65.00
- 今 开61.82
- 成交量 47.75万股
- 最 低 61.79
- 昨 收 60.78
- 总市值 24.40亿
- 52周最高 99.50
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 38.795
- 委 比 -60.27%
- 总股本 3816.01万
- 历史最高 190.85
- 量 比 1.06
- 振 幅 5.28%
- 历史最低 11.60
- 每 手 1
- 风险率 15.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,
03-27 04:32
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine announced the completion of enrollment in its pivotal Phase 3 APOLLO trial for bitopertin in erythropoietic protoporphyria (EPP), with the study size expanded to 183 participants due to high demand. Results are expected in Q4 2026, with plans for an FDA submission and a decision anticipated by mid-2027. Bitopertin, an investigational glycine transporter 1 inhibitor, aims to address unmet needs in EPP treatment.
03-26 20:30
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Truist Securities Maintains Buy on Disc Medicine, Lowers Price Target to $83
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the price target from $114 to $83.
02-28 01:37
Disc Medicine Q4 EPS $(1.62) Beats $(1.68) Estimate
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.62) per share which beat the analyst consensus estimate of $(1.68) by 3.34 percent. This is a 65.31 percent decrease over losses of $(0.98) per share from the
02-27 00:22
财报速睇 | Disc Medicine, Inc. 2025财年年度营收0.00亿美元，同比增长0.0%；归母净利润亏损2.12亿美元，同比亏损扩大94.5%
华盛资讯2月26日讯，Disc Medicine, Inc.公布2025财年年度业绩，公司年度营收0.00亿美元，同比增长0.0%，归母净利润亏损2.12亿美元，同比亏损扩大94.5%。
02-26 21:47
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that its management will present at several upcoming investor conferences, including TD Cowen's 46th Annual Health Care Conference on March 3rd in Boston, MA, and the Leerink Global Healthcare Conference on March 9th in Miami, FL. The company will also participate in investor meetings during the Jefferies Biotech on the Beach Summit on March 10th and the Barc...
02-24 13:30
美股牛股 | Polaryx飙升逾64%，药物临床实验推进方面取得显著进展；麦斯莫医疗、以星综合航运均获高额溢价收购
Polaryx飙升逾64%，药物临床实验推进方面取得显著进展；麦斯莫医疗、以星综合航运均获高额溢价收购，隔夜分别大涨34%，25%>>
02-18 18:30
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
